Business Description
Axsome Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US05464T1043
Total Employee Number:
925Compare
Compare
Traded in other countries / regions
AXSM.USA0HKF.UK19X.Germany1AXSM.ItalyAZSM.Mexico Index Membership
Russell 2000Russell 3000 IPO Date
2015-11-19Description
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.42 | |||||
Equity-to-Asset | 0.11 | |||||
Debt-to-Equity | 2.7 | |||||
Debt-to-EBITDA | -1.28 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 7.46 | |||||
Beneish M-Score | -2.88 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 118.5 | |||||
3-Year EBITDA Growth Rate | 7.8 | |||||
3-Year EPS without NRI Growth Rate | 8 | |||||
3-Year FCF Growth Rate | 13.2 | |||||
3-Year Book Growth Rate | -11.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 53.91 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 31.46 | |||||
9-Day RSI | 34.43 | |||||
14-Day RSI | 37.04 | |||||
3-1 Month Momentum % | 1.64 | |||||
6-1 Month Momentum % | 45.45 | |||||
12-1 Month Momentum % | 95.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.43 | |||||
Quick Ratio | 1.34 | |||||
Cash Ratio | 0.69 | |||||
Days Inventory | 193.93 | |||||
Days Sales Outstanding | 107.95 | |||||
Days Payable | 551.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.4 | |||||
Shareholder Yield % | -0.49 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 93.24 | |||||
Operating Margin % | -23.55 | |||||
Net Margin % | -24.68 | |||||
EBITDA Margin % | -22.68 | |||||
FCF Margin % | -9.27 | |||||
OCF Margin % | -9.18 | |||||
ROE % | -256.9 | |||||
ROA % | -27.58 | |||||
ROIC % | -84.59 | |||||
3-Year ROIIC % | 6.61 | |||||
ROC (Joel Greenblatt) % | -866 | |||||
ROCE % | -62.31 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 284.42 | |||||
PS Ratio | 13.16 | |||||
PB Ratio | 126.24 | |||||
Price-to-Tangible-Book | 308.8 | |||||
EV-to-EBIT | -55.99 | |||||
EV-to-Forward-EBIT | 130.76 | |||||
EV-to-EBITDA | -59.15 | |||||
EV-to-Forward-EBITDA | 117.4 | |||||
EV-to-Revenue | 13.42 | |||||
EV-to-Forward-Revenue | 10.95 | |||||
EV-to-FCF | -144.79 | |||||
Earnings Yield (Greenblatt) % | -1.79 | |||||
FCF Yield % | -0.68 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AXSM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Axsome Therapeutics Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 776.569 | ||
| EPS (TTM) ($) | -3.75 | ||
| Beta | 1.2471 | ||
| 3-Year Sharpe Ratio | 0.97 | ||
| 3-Year Sortino Ratio | 1.94 | ||
| Volatility % | 39.51 | ||
| 14-Day RSI | 37.04 | ||
| 14-Day ATR ($) | 7.708115 | ||
| 20-Day SMA ($) | 212.2945 | ||
| 12-1 Month Momentum % | 95.61 | ||
| 52-Week Range ($) | 112.9 - 260.19 | ||
| Shares Outstanding (Mil) | 52.38 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Axsome Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Axsome Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-23 08:00 | In 180 days | ||
| Annual report for 2026 | 2027-02-23 | In 179 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-23 | In 179 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-03 08:00 | In 68 days | ||
| Third quarter earnings results for 2026 | 2026-11-03 | In 67 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-10 08:00 | 212.74 (+1.24%) | ||
| Second quarter earnings results for 2026 | 2026-08-10 | 212.74 (+1.24%) | ||
| Guidance call for 2026 | 2026-06-15 11:30 | 255.17 (+0.84%) | ||
| Oppenheimer CNS and Neuro-Muscular Summit | 2026-06-10 14:00 | 245.64 (+3.55%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 15:20 | 232.32 (+0.48%) |
Show
Entries
Axsome Therapeutics Inc Frequently Asked Questions
What is Axsome Therapeutics Inc(AXSM)'s stock price today?
The current price of AXSM is $200.72. The 52 week high of AXSM is $260.19 and 52 week low is $112.90.
When is next earnings date of Axsome Therapeutics Inc(AXSM)?
The next earnings date of Axsome Therapeutics Inc(AXSM) is 2026-11-03 Est..
Does Axsome Therapeutics Inc(AXSM) pay dividends? If so, how much?
Axsome Therapeutics Inc(AXSM) does not pay dividend.
Guru Commentaries on NAS:AXSM
GROW Funds
Bullish
2025 Q4
q4 2025 letter
What the manager wrote
Axsome Therapeutics Inc. (AXSM) was a new addition to investor portfolios in January of 2025 and has been a positive contributor since. Axsome is a biopharmaceutical company focused on central nervous system conditions such as Alzheimer’s Disease Agitation, Major Depressive Disorder, Migraines, and Fibromyalgia. Their products target a broad range of serious conditions that impact over 150 million people in the United States. Axsome has 4 products commercially available today with 2 others in late stages of approval. These products have the potential to provide over $16 billion in peak sales in comparison to Axsome’s $630 million of revenue in 2025. Auvelity, an oral drug for major depressive disorder, has quickly ramped to over $500 million in sales in 2025. The FDA has given Axsome accelerated review for a label expansion to Alzheimer’s Disease Agitation, which could be a significant catalyst for the stock.
Press Release
Articles on Axsome Therapeutics Inc
Axsome Therapeutics (AXSM) Q2 Revenue Slightly Misses Estimates; Market Pricing Reflects Growth Expectations
Aug 10, 2026
Axsome Therapeutics Inc (AXSM) Misses Revenue Estimates in Q2 2026 with EPS of $(0.99); GF Score: 30/100
Aug 10, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers